Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

Inclusion Criteria: * Male or non-pregnant female equal or greater than the age of 18 years old and is able to provide informed consent. * Subject is scheduled to undergo an elective catheterization procedure * Hemodynamically stable * At increased risk of developing CIN * Subject has agreed to all follow-up testing. Exclusion Criteria: * Class 4 Congestive Heart Failure (CHF)or a documented left ventricular ejection fraction \< 30% * Is anuric or has undergone renal replacement therapy within the past month, or has a known inability to have a Foley catheter placed. * Subject has been hospitalized or treated medically for any change in renal function over the past week (i.e. dialysis, etc.), or a significant change in renal function is noted at time of screening. * Has documented severe Aortic Stenosis.(Note: Subjects who have undergone successful replacement or repair of their aortic valve are not excluded.) * Currently has a known clinically significant electrolyte imbalance or clinically significant arrhythmias which compromise subject's hemodynamic state. * Patient has severe anemia (hemoglobin \< 8.0 g/dL) at screening * Has received contrast within 10 days of procedure or has a planned additional cardiac or renal or other major surgical procedure within the 7 day follow-up period. * Has ruled in for a Serious Heart Attack within 48 hours of the planned procedure * Has documented respiratory insufficiency as evidenced by an oxygen saturation of \< 90% on room air assessed on day of procedure. * Planned addition, discontinuation or dose adjustment of nephrotoxic drugs * Subject has a known hypersensitivity to furosemide and/or the contrast agent being used. * Subject is currently, plans, or has been enrolled in another clinical study involving use of an investigational drug or device within the prior 30 days. * Subject is pregnant or breastfeeding. * Subject is unable to provide informed consent.